Flu Vaccine Market is expected to grow at a CAGR of 8.8% during the forecast period 2024-2031
The Flu Vaccine Market refers to the industry focused on the development, production, and distribution of vaccines that protect against the seasonal influenza virus. Flu vaccines are designed to stimulate the immune system to fight off influenza, helping to reduce the spread of the virus and prevent serious complications.
Annual flu outbreaks continue to drive strong demand for flu vaccines, particularly among high-risk groups like the elderly, children, and those with weakened immune systems. Market growth is fueled by advancements in vaccine formulations, better distribution networks, and increasing awareness about the need for annual vaccinations. As new flu strains emerge, ongoing research and development are crucial in shaping the future of flu vaccines, further accelerating market expansion.
The flu vaccine offers a cost-effective solution to protect against multiple viral strains. A groundbreaking concept gaining attention in the market is the development of a single vaccine that safeguards against all types of flu.
Manufacturers are also focusing on mini-HA (Hemagglutinin) antigens, which contain components of the flu virus found in several other strains. Universal flu vaccines help reduce the need for annual updates to flu shots, saving researchers and pharmaceutical companies both time and costs.
Download Free Sample PDF: https://www.datamintelligence.com/research-report/flu-vaccine-market
Market Growth Trends:
Ongoing investments boost the production of customized flu vaccines.
Flu vaccines offer a cost-effective solution to combat multiple viral strains. The development of a single vaccine that protects against all flu strains is gaining traction in the market. Manufacturers are also focusing on mini-HA (Hemagglutinin) antigens, which are components of the flu virus shared by several other viruses.
Universal flu vaccines help reduce the need for annual updates, saving both costs for researchers and pharmaceutical companies. Continuous investment in both technology and finances is essential to innovate universal flu vaccines. Players in the flu vaccine market are focusing on enhancing manufacturing processes to increase the production of customized vaccines.
Market Segments:
By Type: Split virus vaccines, Subunit vaccines, Live attenuated virus vaccines
By Distribution Channel: Hospitals, Community clinics, Public health agencies, Workplaces, Retails, Retail pharmacy, Mail order pharmacy
By Application: Adults and Children over 3 years
By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Competitive Landscape
- AstraZeneca
- GlaxoSmithKline PLC
- Sanofi
- Abbott Laboratories
- Seqirus
- Mitsubishi Tanabe Pharma
- Serum Institute of India Pvt. Ltd
- Mylan NV
- GDK Biotechnology
- Hualan Biological Engineering Inc.
- Adimmune Corporation
- Sinovac Biotech
- Changchun Institute of Biological Products
Some major key players follow merger and collaboration strategies to expand their business
GSK acquired clinical-stage biopharmaceutical company Affinivax, Inc. This acquisition provides access to next-generation 24-valent pneumococcal vaccine candidates in phase II development and highly innovative MAPSTM technology
Customize Your Scope: https://www.datamintelligence.com/customize/flu-vaccine-market
Regional Growth:
North America is expected to lead the market throughout the forecast period.
The North America market is projected to maintain its dominant position in the global flu vaccines market, driven by increased government initiatives, such as health programs aimed at raising awareness about influenza, its potential impact, and the importance of flu vaccinations. This study focuses on evaluating the safety of BPL-1357 and explores the role of mucosal immunity in flu protection, investigating whether a strategy that activates both the cellular and antibody aspects of the immune system can offer broader defense against the constantly evolving influenza virus.
Key developments:
The company supplies approximately 80 million doses of Arepanrix and 16 million doses of Flulaval Tetra under the agreement. Both vaccines are produced at the company’s 230,000 ft² Sainte-Foy facility in Quebec. In February 2020, Abbott launched a new flu vaccine offering broader protection against four flu virus strains, compared to three strains in previous versions. This new vaccine is approved for children under the age of 3, providing effective protection against these four strains.




